K-PAX Pharmaceuticals Information

K-PAX Pharmaceuticals is a privately held biotech company currently developing proprietary compounds to treat fatigue, decreased alertness and decreased cognition in Parkinson's disease, Alzheimer’s disease, and cancer-related fatigue. Our patented compound - KPAX002 - is a proprietary modified version of methylphenidate. It is an enhanced, safer CNS stimulant, bolstered by our proprietary mitochondrial technology, with the ability to safely alleviate fatigue and decreased alertness in patients with neurodegenerative and other serious diseases. We have completed several clinical trials which demonstrate that KPAX002 has excellent safety and efficacy at alleviating severe fatigue and decreased alertness symptoms in chronically ill patients. This indication represents a serious unmet medical need with a large population. The FDA is highly supportive of identifying a fatigue treatment in multiple disease states. We are concurrently pursuing several regulatory indications: 1) Parkinson's disease non-motor symptoms 2) Alzheimer's disease decreased alertness 3) Cancer-related fatigue 4) Myalgic encephalomyelitis